Alendronate Sodium
Product Images NDC 68258-3014

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 68258-3014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image For 70mg 4 Count Bottle (Ndc 68258 3014 01)

Label Image For 70mg 4 Count Bottle (Ndc 68258 3014 01)
The text describes a bulk source data for a product manufactured by Cobalt Laboratories, with a product ID of a white to off-white oval tablet, embossed with AN70/ company logo. The bulk source NDC is 16252-0601-44 and each tablet contains 91.37mg of alendronate sodium USP (70mg free acid equivalent). The product is enclosed in a tight or light-resistant container, and it should be dispensed as per the package instructions unless otherwise directed by a physician. The text specifies that the medicine should not be taken while lying down, eating, drinking or while taking other medications for at least 30 minutes. The text provides the contact details of DispenseQuick, the company that packaged the medicine, and warns that it should be kept out of children's reach and stored between 68°-77°F. The description also provides a lot number (5A0244), an MN number (16252060144), and an RX number (20660941).*
FDA Label Image

Figure (Figure02)

Figure (Figure02)
FDA Label Image

Figure (Figure06)

Figure (Figure06)
FDA Label Image

Figure (Figure1and2)

Figure (Figure1and2)
This appears to be a table containing data for a study involving a drug called "Alendronate Sodium" at a concentration of 10mg. There is also a control group receiving a placebo. The data appears to be organized by month, with data points at 0, 12, 24, and 36 months. There are some numbers in the table that are not clear due to errors.*
FDA Label Image

Figure (Figure3)

Figure (Figure3)
FDA Label Image

Figure (Figure4and5)

Figure (Figure4and5)
FDA Label Image

Figure (Figure6)

Figure (Figure6)
FDA Label Image

Fosamax_structure (Fosamax 01)

Fosamax_structure (Fosamax 01)
The text is not-available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.